Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - November 17, 2003
New Jersey has the fifth highest incidence of cumulative reported AIDS cases. This includes the highest percentage of women reported with AIDS and the third highest number of reported pediatric AIDS cases. Medicaid is the single largest payer for these patient populations.
"Drug resistance threatens the recent gains made in treating HIV infection. HIV resistance testing offers clinicians the ability to adjust patient treatment accordingly. This new policy provides further validation of the utility of our resistance tests to manage HIV infection and will expand accessibility for many more patients who are likely to benefit from this important technology," said Tien Bui, ViroLogic's Vice President of Sales and Marketing.
In addition to statewide Medicaid coverage, Medicare and many private payers, including but not limited to Aetna US Healthcare, BlueCross BlueShield, Humana and United HealthCare provide reimbursement and benefit coverage for ViroLogic's HIV drug resistance assays. Several key states and the District of Columbia also provide funding for Ryan White Title programs. Questions about HIV drug resistance testing and reimbursement can be directed to ViroLogic's reimbursement hotline at 1-87-PHENOAID (1-877-436-6243), or to http://www.phenosense.com.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company's products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at http://www.virologic.com.
Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's products for patient testing may not continue to be accepted or that increased demand from physicians or from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic's products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company's PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic's actual events to differ from those projected, please refer to the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.
SOURCE ViroLogic, Inc.
Web Site: http://www.virologic.com
031117
PR031129
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .